Annual report
7317.TEDINET S100W2DL
Period2024-04-01 → 2025-03-31
Filed2025-06-23
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 156
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥9.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥8.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥7.2bn | 2022-04-01 → 2023-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥5.6bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥7.3bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥2.0bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | ¥1.3bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | ¥2.1bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.3bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥675m | 2022-04-01 → 2023-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥409m | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥831m | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.1bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥1.3bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.6bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥953m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥426m | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥165m | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥569m | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥1.6bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥953m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥10.9bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥9.9bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥8.7bn | at 2023-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥6.9bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥6.2bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥4.0bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥4.7bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥6.9bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥5.2bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥3.8bn | at 2023-03-31d | Cons. | Net assets |
| Net assets / equity | ¥3.2bn | at 2022-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥2.8bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.1bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.3bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥4.0bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.2bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.3bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.5bn | at 2022-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥1.3bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥2.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥528m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥915m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥140m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥656m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥746m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥616m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.3bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥485m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥62m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥38m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥183m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.2bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥504m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥43m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥73.38 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥45.03 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥20.17 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥7.85 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥27.46 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥72.55 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥44.43 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥20.02 | 2022-04-01 → 2023-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥7.75 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥26.87 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥324.88 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥244.72 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥178.69 | at 2023-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥153.44 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥134.71 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 63.6% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.3% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 43.2% | at 2023-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 47.0% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 45.1% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 25.7% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 21.3% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 12.1% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.5% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 23.7% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,403 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 1,367 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 1,383 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 1,442 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 1,422 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥3.3bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥3.2bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥3.0bn | 2022-04-01 → 2023-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥2.4bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥3.9bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥149m | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥33m | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥903m | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥347m | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥68m | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥31m | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥673m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥637m | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥253m | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥636m | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥206m | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | −¥320m | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥4m | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥469m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥4.8bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥4.2bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥4.1bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥3.1bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥3.1bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥3.0bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥3.0bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.8bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥1.2bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥1.0bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥1.3bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥1.3bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.6bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥454m | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥29.89 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥9.74 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-15.16 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-0.2 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥22.67 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥29.55 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥9.61 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥22.19 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥10 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥2.5 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥5 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥5 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥20 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥85.11 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥56.75 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥47.4 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥63.58 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥63.9 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 38.0% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.9% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 24.5% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 43.8% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.3% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 42.1% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 18.7% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | -27.3% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | -0.3% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 49.5% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 21,342,800 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 21,223,200 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 5,281,800 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 5,275,400 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,598,500 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 43 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 44 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 39 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 39 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 34 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 56
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2024-04-01 → 2025-03-31 | ¥129m |
| Otherother segments | revenue external | 2024-04-01 → 2025-03-31 | ¥129m |
| Otherother segments | segment assets | at 2025-03-31 | ¥55m |
| Otherother segments | segment profit | 2024-04-01 → 2025-03-31 | ¥31m |
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥18m |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥3m |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥1.9bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥318m |
| Medical Healthcarereportable segment | capex | 2024-04-01 → 2025-03-31 | ¥193m |
| Medical Healthcarereportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥83m |
| Medical Healthcarereportable segment | employees | at 2025-03-31 | 516 pure |
| Medical Healthcarereportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥6.1bn |
| Medical Healthcarereportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥6.1bn |
| Medical Healthcarereportable segment | segment assets | at 2025-03-31 | ¥4.8bn |
| Medical Healthcarereportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥2.0bn |
| Safety Systemreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥319m |
| Safety Systemreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥106m |
| Safety Systemreportable segment | employees | at 2025-03-31 | 877 pure |
| Safety Systemreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥3.4bn |
| Safety Systemreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥3.4bn |
| Safety Systemreportable segment | segment assets | at 2025-03-31 | ¥4.1bn |
| Safety Systemreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥253m |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥512m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥189m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥9.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥9.6bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥9.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥2.3bn |
| Otherother segments | revenue | 2023-04-01 → 2024-03-31 | ¥44m |
| Otherother segments | revenue external | 2023-04-01 → 2024-03-31 | ¥44m |
| Otherother segments | segment assets | at 2024-03-31 | ¥23m |
| Otherother segments | segment profit | 2023-04-01 → 2024-03-31 | ¥19m |
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥2m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥4m |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥944m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥295m |
| Medical Healthcarereportable segment | capex | 2023-04-01 → 2024-03-31 | ¥297m |
| Medical Healthcarereportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥116m |
| Medical Healthcarereportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥5.4bn |
| Medical Healthcarereportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥5.4bn |
| Medical Healthcarereportable segment | segment assets | at 2024-03-31 | ¥3.9bn |
| Medical Healthcarereportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥1.4bn |
| Safety Systemreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥371m |
| Safety Systemreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥155m |
| Safety Systemreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥3.0bn |
| Safety Systemreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥3.0bn |
| Safety Systemreportable segment | segment assets | at 2024-03-31 | ¥5.0bn |
| Safety Systemreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥167m |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥668m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥271m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥8.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥8.4bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥9.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥1.6bn |
| Medical Healthcarereportable segment | employees | at 2025-03-31 | 15 pure |
| Safety Systemreportable segment | employees | at 2025-03-31 | 18 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,481
| Item | Context | Value | Unit |
|---|---|---|---|
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | 2.809 | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 3.408 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 7.413 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 6.846 | |
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | － | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | 1.478 | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 1.564 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 2.210 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 2.176 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E35560-000MedicalHealthcareReportableSegmentMember | 516 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E35560-000SafetySystemReportableSegmentMember | 877 | |
| Number of employees | CurrentYearInstant_OtherReportableSegmentsMember | － | |
| Number of employees | CurrentYearInstant_CorporateSharedMember | 10 | |
| Number of employees | CurrentYearInstant | 1403 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 43 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 12 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 48.2 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 10.5 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 5083000 | JPY |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E35560-000MedicalHealthcareReportableSegmentMember | 15 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E35560-000MedicalHealthcareReportableSegmentMember | 8 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E35560-000SafetySystemReportableSegmentMember | 18 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E35560-000SafetySystemReportableSegmentMember | 4 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_OtherReportableSegmentsMember | － | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_OtherReportableSegmentsMember | － | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 10 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 43 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 12 | |
| Gross scope1 greenhouse gas emissions scope1 and2 greenhouse gas emissions | Prior2YearDuration | 160.45 | |
| Gross scope1 greenhouse gas emissions scope1 and2 greenhouse gas emissions | Prior1YearDuration | 213.54 | |
| Gross scope1 greenhouse gas emissions scope1 and2 greenhouse gas emissions | CurrentYearDuration | 223.25 | |
| Gross scope2 greenhouse gas emissions scope1 and2 greenhouse gas emissions | Prior2YearDuration | 3139.94 | |
| Gross scope2 greenhouse gas emissions scope1 and2 greenhouse gas emissions | Prior1YearDuration | 3289.20 | |
| Gross scope2 greenhouse gas emissions scope1 and2 greenhouse gas emissions | CurrentYearDuration | 2957.55 | |
| Gross scope1 and2 greenhouse gas emissions scope1 and2 greenhouse gas emissions | Prior2YearDuration | 3300.39 | |
| Gross scope1 and2 greenhouse gas emissions scope1 and2 greenhouse gas emissions | Prior1YearDuration | 3502.74 | |
| Gross scope1 and2 greenhouse gas emissions scope1 and2 greenhouse gas emissions | CurrentYearDuration | 3180.80 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | 7 | |
| Research and development expenses research and development activities | CurrentYearDuration | 43749000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 530476000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E35560-000MedicalHealthcareReportableSegmentMember | 193150000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E35560-000SafetySystemReportableSegmentMember | 319238000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_CorporateSharedMember | 18087000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 21342800 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 21354800 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 21342800 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 21354800 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 2 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |